Less Ads, More Data, More Tools Register for FREE

Agreement

26 Aug 2008 10:00

RNS Number : 9876B
Aortech International PLC
26 August 2008
 



AorTech Signs Agreement to Supply Its Biostable Polyurethane to 

Vascular Connector Company 

AorTech International plc (AIM: AOR) the biomaterials and medical device development company, today announces an agreement with an emerging arteriovenous (AV) fistula company to use AorTech's proprietary biostable co-polymer Elast-Eon™ in their products. This agreement marks AorTech's entry into the estimated $300 million per year U.S. AV fistula connector arena.

The deal includes a nominal upfront payment, $250K in milestone payments, provisions for polymer sales and a single digit royalty.

"The use of Elast-Eon in vascular connectors is a natural extension of the portfolio of uses in other blood-contacting products. Elast-Eon's best in class biostability, processibility and blood-contacting performance make it an excellent choice for this application," said Frank Maguire, AorTech Chief Executive Officer.

AorTech develops and manufactures biostable, implantable polymers, including Elast-Eon, the world's leading long-term implantable copolymer. With hundreds of thousands of successful long-term human implants, Elast-Eon is currently used in cardiology, orthopaedic, urological and gastroenterological applications, including pacing leads, cardiac cannulae and stents. Devices manufactured from Elast-Eon have multiple US FDA PMA approvals, CE Marks and Japanese Ministry of Health approval.

Elast-Eon's biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. It can be processed using conventional thermoplastic extrusion and molding techniques. AorTech provides a range of materials in a variety of application-specific formulations for use in medical devices and components.

26 August 2008

For further information please contact:

AorTech International plc

Frank Maguire, Chief Executive

Tel: + 1 801 201 4336

Evolution SecuritiesBobbie Hilliam / Chris Clarke

Tel: +44 20 7071 4300

AorTech International plc

Sarah Price, Investor Relations

Tel: + 1 801 550 4349

e-mail sprice@aortech.com

  

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRGIGDISGDGGIL

Related Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Back to RNS